14,650 views
Denosumab is an anti-resorptive drug that has demonstrated good efficacy in the treatment of postmenopausal osteoporosis and other forms of osteoporosis. Even when used long-term, it continues to reduce the risk of fracture, unlike bisphosphonates whose action stabilizes after 3-4 years. Even after 10 years of use, the risk of fracture continues to decrease. However, it is important that denosumab therapy is not interrupted suddenly, so as not to lose the benefits acquired. To counteract this rapid loss of anti-fracture efficacy after denosumab suspension, it has been suggested to immediately continue with an amino-bisphosphonate (pharmacological consolidation) in order to create a lasting suppression of bone turnover with a long-term tail effect. We have explored the topic in depth with Prof. Iacopo Chiodini who gave a report on the topic during the GIBIS National Congress held in Rome.